Buradasınız

Anasayfa » Content

Hastaneye Başvuran Malnutrisyonu ve/veya Tekrarlayan Akciğer Enfeksiyonu Olan Çocuklarda Kistik Fibrozis Sıklığı Araştırılması

The Eveluation of Cystic Fibrosis Frequency in Children with Malnutrition and/ or Recurrent Pulmonary Infection

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Cystic fibrosis (CF) which is occurred by mutations in the gene regulation of transmembrane message shows autosomal recessive inheritance. It is also the most common fatal diseases in white race. The frequency of disease is estimated as 1/2500-1/3500 in white race, 1/1700 in African Americans. But the frequency of CF is not known for our countries. In this study, the frequency of disease was tried to find in children with malnutrition and/or recurrent pulmonary infections who admitted to hospital. This prospective study was conducted between February 2007 and January 2010 and children with malnutrition and/or recurrent pulmonary infections were enrolled the study. The diagnosis CF was made by using positive sweat test and appropriate clinical findings and rule out of other diseases which also caused recurrent pulmonary infections or malnutrition. A total of 491 children were enrolled the study. The mean age of children was 26,1±35.01 months with the range of 2-216 months. Of all children, 335 (68.3%) were male and 156 (31.7%) were female. Positive sweat test was found in 35 (7.1 %) children. The frequency of CF was found to be 5.3 % in children with malnutrition and 8.8 % in children with recurrent pulmonary infections. Finally we emphasized one more times that CF should be keep in mind in children with malnutrition and/or recurrent pulmonary infections due to its early diagnosis and prevention of late complications.
Bookmark/Search this post with
Abstract (Original Language): 
Kistik fibroz (KF), transmembran ileti regülasyonu genindeki mutasyon sonucu oluşur ve otozomal resesif kalıtım gösteren beyaz ırkın en sık rastlanan ölümcül hastalığıdır. Hastalığın sıklığı beyaz ırkta 1/2500-1/3500, Afrika kökenli Amerikalılarda 1/1700 civarındadır. KF’nin ülkemizdeki sıklığı ise bilinmemektedir. Bu çalışmada, hastaneye başvuran tekrarlayan akciğer enfeksiyonu ve/veya malnutisyonu olan çocuklarda Kistik fibrozis sıklığının bulunması amaçlanmıştır. Çalışmaya Şubat 2007 ile Ocak 2010 tarihleri arasında kliniğimize başvuran tekrarlayan akciğer ve/ veya malnutrisyonu olan vakalar alındı. Vakalarda kistik fibrozis tanısı, kistik fibrozis kliniği ile uyumlu bulgulara sahip olma, diğer hastalıkların dışlanması ve ter testi pozitifliği esaslarına göre kondu. Çalışmaya 491 çocuk vaka alındı. Vakaların yaşları minimum 2, maksimum 216 ay olup ortalama 26,1±35.01 ay idi. Vakaların 335 (%68.3)’si erkek, 156 (%31.7)’ü kız idi. Çalışmaya alınan vakalar ter testi sonucuna göre değerlendirildiğinde pozitif ter testi vaka sayısı 35 (%7.1) idi. Tekrarlayan akciğer enfeksiyonu olan çocuklarda KF sıklığı %5.3, malnutrisyonu olanlarda %8.8, malnutrisyonu ve/ veya tekrarlayan akciğer enfeksiyonu olan çocuklarda ise %7.1 (%95 Confidence interval 3.9 -9.2) olarak bulundu. Bu çalışma ile biz hastaneye başvuran malnutrisyon ve/veya tekrarlayan akciğer enfeksiyonu olan olgularda Kistik Fibrozis tanısının erken konulması ve geç komplikasyonlarının önlenmesi için mutlaka akılda tutulması gerektiğini vurgulamak istedik.
FULL TEXT (PDF): 
PDF icon tekrarlayan-akciger-enfeksiyonu-olan-cocuklarda-kistik-fibrozis-sikligi-arastirilmasi.pdf
  • 4
138-141
  • Turkish

REFERENCES

References: 

1. Knowles MR, Friedman KJ, Silverman LM. Genetics, Diagnosis
and Clinical Phenotype. In: Yankaskas JR, Knowles MR, eds.
Cystic fibrosis in adults. New York: Lippincott-raven 1999:27-
42.
2. Davis PB. Clinical pathophysiology and manifestations of lung
disease. In: Yankaskas JR, Knowles MR, eds. Cystic fibrosis in
adults. New York: Lippincott-raven 1999:45-67.
3. Fraser RG, Peter Pare JA, Pare PD, Fraser RS, Genereux GP.
In: Bralow L. Diseases of the airways. Diagnosis of Diseases
of the Chest. 3rd ed. Philadelphia: W.B. Saunders Company;
1990: 1208-19
4. Wilcken B, Travert G. Neonatal screening for cystic fibrosis:
present and future. Acta Paediatr Suppl. 1999; 88: 33-5.
5. Csiszer E, Hajdu K. Respiratory insufficiency and pregnancy in
cystic fibrosis. Orv Hetil. 1999; 140: 2639-42.
6. Schwarz MJ, Malone GM, Haworth A, Cheadle JP, Meredith AL,
Gardner A, Sawyer IH, Connarty M, Dennis N, Seller A, et al.
Cystic fibrosis mutation analysis: report from 22 U.K. regional
genetics laboratories. Hum Mutat. 1995; 6: 326-33,
7. Colten RH. Cystic Fibrosis. In: Braunwald E, Isselbacher KJ,
Petersdorf RG, et al, ed. Harrison’s Principles of Internal
Medicine 2. Hamburg: McGraw-Hıll Book Company. 1987;
1085-7.
8. Stern RC, Doershuk Durumm ML. 3849+10 kb C>T mutation
and disease severity in cystic fibrosis. Lancet. 1995; 346:
274-6.
9. Neyzi O, Ertuğrul T. Pediatri 2. İstanbul: Nobel Tıp Kitabevi.
1990; 867-71.
10. Castellani C, Tamanini A, Mastella G. Protracted neonatal
hypertrypsinogenamia, normal sweat chloride, and cystic
fibrosis. Archives of Disease in Childhood. 2000; 82: 481-2.
11. Mueller RF, Young ID. Emery’s Elements of Medical Genetics.
Singapore: Produced by Longman. 1997; 233-43,
12. Nousia-Arvanitakis S. Cystic fibrosis and pancreas: recent
scientific advances. J Clin Gastroenterol. 1999; 29: 138-42.
13. Dodge JA. Why screen for cystic fibrosis? A clinician’s view.
Acta Paediatr Suppl. 1999; 88: 28-32
14. Göçmen A, Özçelik U, Kiper N, Erdem H. Kistik fibrozisli 104
hastanın klinik ve laboratuar özellikleri. Çocuk Sağlığı ve
Hastalıkları Dergisi 1995; 38: 21-3.
15. Kaya A, Derman U, Yaramış A ve ark. Güneydoğu Anadolu
bölgesindeki kistik fibrozisli 23 hastanın klinik ve laboratuar
özellikleri. Çocuk Sağlığı ve Hastalıkları Dergisi 2000; 43: 345-
51.
16. Whittier S, Hopfer RL, Knowles MR et al. Improved recovery
of mycobacteria from respiratory secretions of patients with
cystic fibrosis. Clin Microbiol 1993; 31: 861-4.
17. Von Graevenitz A. Acinetobacter, Alcaligenes, Moraxella and
other nonfermentative gram negative bacteria. In: Murray PR,
Baron EJ, Pfaller MA et al, eds. Manual of clinical microbiology.
6th ed. Washington DC: ASM Press, 1995.
18. Noone PG, Knowles MR. Standart therapy of cystic fibrosis
lung disease. In: Yankaskas JR, Knowles MR eds. Cystic
fibrosis New York: Lippincott- Raven 1999: 145-73.
19. Pedersen SS, Jensen T, Hoiby N et al. Management of
Pseudomonas aeruginosa lung infection in Danish cystic
fibrosis patients. Acta Pediatr Scand 1987; 76: 955-61.
20. Ramsey BW, Dorkin HL, Eisenberg JD et al. Efficacy of
aerosolized tobramycin in patients with cystic fibrosis. N Eng J
Med 1993; 328: 1740-6.
21. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration
of inhaled tobramycin in patients with cystic fibrosis. N Eng J
Med 1999; 340: 23-30.
22. Couper RTL, Corey M, Moore DJ et al. Decline of exocrine
pancreatic function in cystic fibrosis patients with pancreatic
insufficiency. Pediatr Res 1992; 32: 179-182.
23. Rothbaum RJ. Gastrointestinal complitations. In: Orensitein
DM, Stern RC, eds. Treatment of the hospitalized cystic
fibrosis patient. New York: Marcel Dekker Inc: 1998: 135-73.
24. Smyth RL, Ashby D, O’Hea U et al. Fibrosing colonopathy in
cystic fibrosis: results of a case-control study. Lancet 1995;
346: 1247-51.
25. Consensus Conferences. Consensus document
recommendations for management of liver and biliary tract
disease in cystic fibrosis. Cystic Fibrosis Foundation. 1999; 9:
1-21
26. Colombo C, Crosignani A, Melzi ML et al. Hepatobiliary system.
In: Yankaskas JR, Knowles MR eds. Cystic fibrosis in adults.
New York: Lippincott-Raven 1999; 309-24.
27. De Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC.
Ursodeoxycholic acid in chronic liver disease. Gut 1991; 32:
1061-5.
28. Cottig J, Lentze M, Reichen J. Effects of ursodeoxycholic acid
treatment on nutrition and liver function in patients with cystic
fibrosis and longstanding cholestasis. Gut 1990; 31: 918-21.
29. Colombo C, Battezati PM, Podda M et al. The Italian Group for
the study of Ursodeoxycholic acid in cystic fibrosis; a doubleblind multicenter trial. Hepatology 1996; 23: 1484-90.

Thank you for copying data from http://www.arastirmax.com